A5043181400- Lung Cancer Treatments and Mutations
- Lung Cancer Research Studies
- Cancer therapeutics and mechanisms
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
- Sperm and Testicular Function
- PI3K/AKT/mTOR signaling in cancer
- Neuroendocrine Tumor Research Advances
- Cancer Genomics and Diagnostics
- Neuroblastoma Research and Treatments
- Protein Tyrosine Phosphatases
- Synthesis and biological activity
- Lipid metabolism and biosynthesis
- Melanoma and MAPK Pathways
- Healthcare and Venom Research
- Acute Lymphoblastic Leukemia research
- Reproductive Biology and Fertility
- Urinary Bladder and Prostate Research
- Vitamin D Research Studies
- Multiple Myeloma Research and Treatments
- T-cell and Retrovirus Studies
- Cytokine Signaling Pathways and Interactions
- Ion Channels and Receptors
- Lung Cancer Diagnosis and Treatment
- Advanced Breast Cancer Therapies
Henan Cancer Hospital
2011-2025
Zhengzhou University
2025
Air Force Medical University
2024-2025
Kunming Medical University
2024
China Medical University
2024
First Hospital of China Medical University
2024
Taletrectinib, a highly potent, CNS-active,
3008 Background: Resistance to KRAS G12C inhibitor in non-small cell lung cancer (NSCLC) can be overcome by SHP2 blockade. This concept was tested Phase I study of glecirasib combined with JAB-3312 patients (pts) p.G12C mutated tumors. Promising preliminary data safety and response were reported at the 2023 ESMO (653O). Here, we present updated efficacy treatment progression-free survival (PFS) combination therapy front-line NSCLC. Methods: The phase 1/2a [NCT05288205] evaluated plus solid...
The estrogen receptor alpha (ERα) plays an important role in male reproduction and fertility. Its activity is modulated by phosphorylation of multiple amino acid residues. ERα phosphorylated at serine 305 (S305) human cells (homologous with 309 mice) induces ligand-independent activity. Here, we studied the effect S309 on reproductive function mice. ERα309 (p.S309A, ERαS309A) knock-in (KI) mice were generated homologous recombination mouse embryonic stem (ES) cells. S309A KI males subfertile...
Abstract HA121-28, a promising multikinase inhibitor, mainly targets rearranged during transfection (RET) fusions and selectively vascular endothelial growth factor receptor-2, receptor, fibroblast receptor 1-3. The safety, pharmacokinetics, efficacy of HA121-28 were assessed in advanced solid tumors (phase 1, ClinicalTrials.gov NCT03994484) RET fusion-positive non-small-cell lung cancer (RET-TKI naive NSCLC, phase 2, NCT05117658). was administered orally doses range from 25 to 800 mg under...
Antibody–drug conjugates (ADCs) have emerged as a transformative modality in the treatment of solid tumors. YL201, novel B7H3-targeting ADC, leverages tumor microenvironment activable linker-payload platform, coupled with topoisomerase 1 inhibitor via protease-cleavable linker. Here we report findings from large-scale, global, multicenter, phase trial evaluating safety, pharmacokinetics and preliminary efficacy YL201 patients advanced tumors refractory to standard therapies. The included...
Abstract Cryptorchidism is associated with an increased risk of male infertility and testicular cancer. Persistent exposure to high temperature in cryptorchidism can lead the apoptosis spermatogenic cells. Transient receptor potential vanilloid 1 (TRPV1), a thermosensitive cation channel, has been found have differential effects on various processes. However, whether TRPV1 involved cell induced by remains unclear. Herein, we first observed expression pattern testes mice experimental...
Abstract Background: JYP0322 is a potent, brain-penetrant and highly selective ROS1 inhibitor, demonstrating over 100-fold selectivity for compared to TRKA sub-nanomolar potency against the G2032R resistance mutation. designed simultaneously address key clinical challenges including mutations, tumor brain metastases while avoiding off-target neurotoxicity associated with TRK inhibition. Method: The Phase I study (NCT06128148) was evaluate safety, pharmacokinetics (PK), preliminary efficacy...
9015 Background: Platinum-based chemotherapy is the 1 st line standard of care for NSCLC patients with EGFR exon 20 insertion mutations (Exon20ins), anti-PD(L)1 frequently used as well. Here we present anti-tumor activity sunvozertinib in these whose disease had progressed on therapies from two ongoing phase 1/2 studies (WK-KONG1, NCT03974022 and WU-KONG2, CTR20192097). Based data, was granted Breakthrough Therapy Designation by both US FDA China NMPA. Methods: The objective this study to...
3012 Background: MHB088C is an investigational B7H3-directed ADC, created by coupling a humanized anti-B7H3 monoclonal antibody with highly potent DNA topoisomerase I inhibitor (5~10 times more than DXd). Preclinical studies demonstrated robust binding affinity, superior internalization rates, powerful tumor killing activities (3~10 the DS-7300a analog in CDX models) and favorable safety profile no unique toxicities observed GLP study as compared to other B7H3 ADCs occurrences of...
Abstract Purpose To evaluate the safety, tolerability, and preliminary efficacy of multiple doses pegylated irinotecan (JK1201I) as a second‐line monotherapy for treating small‐cell lung cancer (SCLC) patients. Methods According to “3 + 3” dose‐escalation principle, patients received intravenous JK1201I at 180 or 220 mg/m 2 once every 3 weeks four cycles. Progression‐free survival (PFS), overall (OS), median progression‐free (mPFS), (mOS) were evaluated. The Kaplan–Meier method was used...
Chemotherapy remains the standard-of-care for many patients with advanced non-small-cell lung cancer (NSCLC), but acquired resistance presents challenges. The aim of this open-label, multicenter phase 2 clinical trial was to determine efficacy and safety utidelone, a novel genetically engineered epothilone analog microtubule-stabilizing agent, as third- or later-line treatment metastatic NSCLC. Patients who had failed standard second-line (including platinum-containing chemotherapy targeted...
8520 Background: Taletrectinib, a highly potent, next-generation, central nervous system–active, selective ROS1 tyrosine kinase inhibitor (TKI), was previously reported to provide high overall and intracranial (IC) response rates, prolonged progression-free survival (PFS), activity against G2032R with favorable tolerability. We report updated data from the TRUST-I study (NCT04395677), largest clinical trial date conducted in patients living ROS1+ NSCLC. Methods: TRUST-I, multicenter,...
e15007 Background: MHB036C, an investigational ADC, comprises a humanized anti-TROP2 monoclonal antibody engineered to minimize potential toxicities mediated by non-specific uptake, and highly potent DNA topoisomerase I inhibitor (5~10 times more than DXd) conjugated via stable cleavable linker. In preclinical studies, MHB036C demonstrated superior tumor killing activities the DS-1062a analog) favorable safety profile with no unique as compared other TROP2 ADCs occurrences of interstitial...